Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III, randomized, controlled, open-label, multicentre, three arm study to compare the efficacy and safety of a dual-boosted HIV-1 protease inhibitor regimen of fosamprenavir/lopinavir/ritonavir 1400mg/533mg/133mg twice daily and an increased dosage regimen of FPV [fosamprenavir]/RTV [ritonavir] 1400mg/100mg BID [bidaily] versus the standard dosage regimen of FPV/RTV 700mg/100mg BID for 24 weeks in multiple-PI [protease inhibitor] experienced, HIV-infected adults experiencing virological failure

Next Previous
X
Search
Trial Profile

A phase III, randomized, controlled, open-label, multicentre, three arm study to compare the efficacy and safety of a dual-boosted HIV-1 protease inhibitor regimen of fosamprenavir/lopinavir/ritonavir 1400mg/533mg/133mg twice daily and an increased dosage regimen of FPV [fosamprenavir]/RTV [ritonavir] 1400mg/100mg BID [bidaily] versus the standard dosage regimen of FPV/RTV 700mg/100mg BID for 24 weeks in multiple-PI [protease inhibitor] experienced, HIV-infected adults experiencing virological failure

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fosamprenavir (Primary) ; Lopinavir/ritonavir; Ritonavir
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms TRIAD
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 02 Sep 2021 This trial has been completed in Spain, according to European Clinical Trials Database.
    • 01 Aug 2009 Results published in the Journal of Antimicrobial Chemotherapy.
    • 09 Nov 2007 Status changed from recruiting to discontinued. This study has been terminated due to incomplete data.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top